Clinical Trial

A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 3, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild essential hypertension
Trial Details
NCT Number NCT07152444
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Uncontrolled Hypertension
Enrollment 78 participants
Start Date 2025-09
Primary Completion 2026-05 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-03